Skip to main content
. 2019 Apr 19;8(5):1943–1957. doi: 10.1002/cam4.2095

Figure 2.

Figure 2

Mode of action of fulvestrant and other targeted therapies in cancer cells. AKT, protein kinase B; CDK4/6, cyclin‐dependent kinases 4/6; EGFR, epidermal growth factor receptor; HER2/3, human epidermal growth factor receptor 2/3; IGFR, insulin‐like growth factor receptor; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol‐3‐kinase; OR, estrogen receptor. Adapted from Peter, Eur. Oncol. Haematol., 2017;13(2):127‐13358